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Objectives: This study was conducted to estimate the annual societal costs in Iran associated with the treatment of ischemic
and hemorrhagic stroke patients using a prevalence-based cost-of-illness framework.
Methods: A prevalence-based cost-of-illness framework was applied. Key model parameters included annual incidence of
stroke; use of stroke therapies, medicines, and other medical care resources; work days missed; wage rates; and annual
costs per patient. The outcomes measured were total societal costs, societal cost per year, and societal cost per patient-year.
Results: For the studied 1940 patients, the economic burden of stroke in 2018 was roughly $4 081124 in US dollars. Bearing in
mind that there are about 100 000 cases of stroke, including new (35%) and old cases (65%) of 2 types of strokes, per year in
Iran, the estimated economic impact is about $368 925 000. Lodging, medication, and consumables account for 69% of all
direct medical costs ($299 959). The main cost factors were mortality costs (76.6%) and disability costs (14.7%).
Conclusion: The economic impact of stroke in Iran is considerable. The premature deaths and resulting disability from strokes
accounted for the main productivity losses and all societal costs of stroke (approximately 91% of all costs). To control hy-
pertension and decrease the burden of stroke, especially in elderly age groups, it is recommended that Iran look into how to
focus on and expand healthy lifestyle choices.
Keywords: costs and cost analysis, cost of illness, disease management, Iran, stroke.
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The “Global Burden of Disease, Injuries, and Risk Factors
Report” in 2015 revealed that stroke is currently the second
leading cause of deaths and long-term disabilities worldwide.1 In
the last decade, the incidence of strokes, survivors, and stroke-
related deaths, in addition to disability-adjusted life-years, has
increased globally. For example, ischemic stroke death has
increased from 2 182 865 deaths in 1990 to 3 272 924 in 2013.
Presently, 3% to 4% of total healthcare expenditures (HCE) in
Western countries are spent on strokes.2 Substantial decreases in
stroke incidence, mortality, and disability-adjusted life-years have
been achieved in high-income countries, but these success stories
have not been mirrored in developing countries, where the inci-
dence has risen sharply.1,3 Recent studies have shown that the
prevalence of stroke is significantly higher in Iran compared with
Western countries, particularly hemorrhagic stroke and in
younger populations.4-6 Population-based studies are needed in
stroke research and policy makers are interested in understanding
the economic costs of illnesses for health resource allocation and
to evaluate the potential benefits and costs of public health-
related interventions.7 The annual direct costs of stroke were
estimated at V26.6 billion in 2010 for the European Union, Iceland,99/$36.00 - see front matter ª 2020 ISPOR–The professional society for heNorway, and Switzerland.8 Based on primary searches, the eco-
nomic burden caused by stroke has not been well explored in
developing countries. Similarly, there is limited knowledge of the
costs of the economic burden (both direct and indirect costs) of
stroke in Iran. This article is an attempt to provide basic epide-
miological and cost data on stroke, especially to estimate the cost
of illness and economic burden of stroke in Iran in 2018 from a
societal perspective.Methods
The main approaches to estimating the burden of diseases are
“prevalence-based” and “incidence-based” methods.9 The
prevalence-based method estimates the costs of an illness that
occur concurrently with overall prevalent cases over a specified
time period, usually over a year. On the other hand, an incidence-
based method estimates the lifetime costs of an illness from the
beginning of symptoms until the disease either resolves or results
in death; it also incorporates a discount rate for the year when the
disease was diagnosed.10 In this study, a prevalence-based method
was used to estimate the costs of illness imposed by ischemic and
hemorrhagic stroke in Iran in 2018. This study was conductedalth economics and outcomes research. Published by Elsevier Inc.
Table 1. The direct medical cost of strokes in Iran in 2018 (estimated in US dollars).
Procedures Number of patients Mean cost Total cost Total cost (percent)
Lodging 1940 $98 $190 408 44%
Medicine and consumables 1940 $56 $109 551 25%
Clinical visits 1940 $19 $37 076 9%
Other clinical costs 1940 $15 $28 773 6%
Laboratory visits 1864 $14 $25 914 6%
CT scans 1616 $9 $14 011 3%
Tapes 1802 $6 $11 398 3%
Radiography 740 $11 $8346 2%
Surgery 446 $18 $8099 2%
Total 1940 $223 $433 575 100%
CT indicates computed tomography.
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nonmedical, and indirect costs of both the inpatient and outpa-
tient population.
Model Overview and Design
A cross-sectional prevalence-based cost-of-illness approach
was applied. To analyze the full costs, the model included direct
medical, direct nonmedical, and indirect costs associated with
both ischemic and hemorrhagic stroke. Direct medical costs meant
the medical expenditures for procedures and services, such as
physician visits, medicines, hospital stays, and diagnostic tests
related to stroke. Direct nonmedical costs included travel ex-
penses associated with receiving treatment. Indirect costs
measured lost work productivity because of missed days of ac-
tivity and lost productivity because of premature deaths in the
working age groups (15 to 64) or time spent away from the
workplace. All costs were converted into US dollars using the 2018
mean exchange rate (1 USD = Rial 100 000).11
Context and Population
The number of stroke patients, direct medical costs, and
mortality and survival rate were extracted from various re-
sources and registries. We used the hospitals affiliated with the
Mashhad University of Medical Sciences health information
system registries. Patients included all new cases and old cases of
both types of stroke referred or admitted to any of these hos-
pitals in 2018.
Direct Medical Costs
To estimate the direct medical costs, we categorized the whole
disease costs into 9 cost categories: lodging, medicines and con-





Employed patients 570 4.04
Unemployed patients 1370 4.48
Accompanies 1940 4.35
Totalscans, tapes, radiography, surgery, and other clinical costs. To es-
timate the total direct medical costs, we measured the average
costs of each category and the number of patients who received
treatment in the hospitals affiliated with the Mashhad University
of Medical Sciences. The average costs of each category were then
multiplied by the number of patients who received treatment in
these hospitals in 2018. To estimate the average costs of inpatient
care, we reviewed the medical records of patients. To identify and
estimate real clinical process items for stroke patients, we used
the latest national clinical guideline for stroke. We also checked
the latest circular of Iranian medical tariffs related to stroke pa-
tients as a means to extract each clinical item’s cost. To ensure the
accuracy of items and costs, we conducted a short discussion with
a vascular neurologist.12-14
Direct Nonmedical Costs
Because of the lack of data on nonmedical costs of stroke pa-
tient, we only estimated the transportation costs. This cost and the
average number of trips made by patients were extracted through
interviews with patient family members. Other direct nonmedical
costs were not included in the analyses.
Indirect Costs, Patient Time Costs, Mortality Costs, and
Disability Costs
To estimate the indirect costs, a human capital approach was
used. Moreover, as an assumption, the monetary value of pro-
ductivity lost because of morbidity and mortality equaled the
current wages of patients. We used a prevalence-based approach
for 1-year costs; the long-term morbidity costs associated with
strokes were not included in the cost analyses.
The average number of days that each patient lost because of






2302.8 $10 $23 028
6137.6 $5 $30 688
8439 $5 $42 195
$95 911
Table 3. The mortality costs for stroke in Iran in 2018 (estimated in US dollars).
Age group (year) Number of deaths Mean mortality cost Total cost
30-39 4 $105 575 $422 300
40-49 2 $61 419 $122 838
50-59 34 $31 230 $1 061 820
60-69 42 $11 562 $485 604
70 # 112 $899 $100 688




Table 4. The summary of all types of costs in US dollars for strokes in Iran in 2018.






Direct medical costs $433 575 $223 $22 300 000
Transportation costs $87 300 $45 $4 500 000
Patient time costs $95 911 $49 $4 900 000
Disability costs $1 271 088 $728 $54 600 000 (for 75 000 survived patients in one year in Iran)
Mortality costs $2 193 250 $11 305 $282 625 000 (for 25 000 death in on year in Iran)
Total annual costs $4 081 124 $12 350 $368 925 000
Figure 1. Societal cost components of stroke in Iran, 2018.
METHODOLOGY 79also by interviewing the patient’s family. The number of deaths,
years of potential life lost, and the value of each year were
measured to estimate the mortality costs.15 The potential life-
years lost were defined as the remaining years of life at the age
of death based on World Bank life expectancy data for Iran.16,17 To
estimate the disability costs, we considered the costs associated
with the patient’s rehabilitation programs.Results
The direct medical costs of stroke patients are shown in Table 1.
The 1940 cases were admitted or referred to Mashhad University
of Medical Science–affiliated hospitals in the study period. About
58% of the patients were men and the mean age for both women
and men was about 65 years old. Because all patients had lodging,
80 VALUE IN HEALTH REGIONAL ISSUES - 2021medicine, consumables, and visit costs, the expenditure of these
components were calculated for all incident cases of stroke.
The greatest part of the direct medical cost (44%) was the cost
of lodging. Lodging, medicine, and consumables accounted for 69%
of all direct medical costs ($299 959).
In total, patients spent $87 300 on transportation during their
treatment. The average number of trips taken by patients and
family were 15 trips, based on the 64 people who were inter-
viewed. The mean cost per trip was estimated at approximately
$3. The minimum wage rate in Iran for 2018 was assigned to un-
employed patients. We estimated that the patient's time cost was
about $95 911 for all 1940 included patients (Table 2).
Based on the opinions of a team of rehabilitation specialists
(including occupational therapy, physiotherapy, and speech ther-
apy practitioners), a patient who has had a stroke will need at
least 2 rehabilitation sessions per week for a year. Moreover, the
rehabilitation tariff based on telephonic interviews with 3 reha-
bilitation clinics was $7 per session. In total, 1746 out of the 1940
patients in this study survived after stroke (90%), amounting to a
cost of $1 271 088 in therapy.
In Table 3, we provide the age-specific mortality rate and the
costs of mortality resulting from strokes. The number of mortal-
ities in the studied hospitals in 2018 was 194 cases (or 10% of all
stroke patients referred to the studied hospitals). Most of the
patients who died were in the age group above 70 years (57%), and
the total mortality cost was about $2 193 250.
The per case cost of mortality was about $11 305. According to
the Iranian Ministry of Medical Health and Education Reports, the
prevalence of stroke cases in Iran is about 100 000 per year
(including 35% new and 65% old cases); of the 100 000 cases,
approximately 25 000 lead to death.18,19 We also presented the
summarized costs as per patient’s annual costs, as well as total
annual societal costs for the country in the year 2018 (Table 4).
Overall, the economic burden of stroke in 2018 for the studied
1940 patients was approximately $4 081 124. The annual cost per
patient was $12 350. The total annual societal costs were thus
about $368 925 000. The main components of the cost were
mortality costs (76.6%) and disability costs (14.7%) (Fig. 1).Discussion
This study was one of the first attempts to estimate the eco-
nomic impact of stroke in Iran. The present study on economic
burden used a prevalence-based method and human capital
approach to estimate the societal annual costs. We showed that
the total economic burden of stroke patients in studied hospitals
was $4 081 124 for all 1940 patients in 2018 and most of these
costs were because of productivity losses resulting from deaths.
As a result, one stroke patient imposes $12 350 annually. Bearing
in mind the approximately 100 000 strokes in Iran each year,
including about 35 000 new cases,18,19 it is estimated that stroke
imposed a cost of $368 925 000 to Iran in 2018. At first glance,
these estimated costs may look low compared with similar
studies,20-22 but it is important to consider that Iran is involved in
an economic crisis and its currency value has weakened in recent
years compared with the US dollar.23 The mean exchange rate in
2018 was 100 000 Iran Rials per 1 US dollar. Xu et al estimated
that the economic impact of stroke in Euros was V1.74 billion for
England, Wales, and Northern Ireland for the year 2015.24 In line
with other population-based economic impact studies, lodging,
medicine, and consumable costs accounted for the main part of
the direct medical costs.25 Some authors argue that the costs of
medical services in Iran are less than in some other Middle
Eastern countries and developed countries.26 For example, inIran, the public services tariff is much lower than that in the
private sector.27,28 Nevertheless, in the present study, the medical
costs accounted for about 6.0% of all societal costs in studied
patients. In line with similar studies,2,29,30 the main cost factor
was the mortality cost, which accounted for 76.6% of all societal
costs.22 Most patients who died were in the age group above 70
years (57%); 79% of stroke patients who died were above 60
years, coinciding with other studies, which have noted that 50%
of all strokes occur in people over the age of 75 and 30% in people
over the age of 85. Ultimately, 14.79% of all societal costs in Iran
for stroke care fell on rehabilitation. Meanwhile, it was reported
that rehabilitation care consumed 40% of all stroke costs in
Sweden in 2012.21 Similarly, a systematic review on poststroke
care costs revealed that rehabilitation services were the main
cost driver of poststroke care in almost all of the included
studies.31
Applying a societal approach for cost analysis and considering
the disability costs are the strengths of the present study. Never-
theless, there are some recognized limitations of our study. First,
as we mentioned, the medical care tariff in Iran may not show the
real costs imposed on the health system. Second, the widely used
human capital approach underestimates the value of life for some
groups of people.32 Third, this study was conducted based on
hospitalized patient data in public hospitals affiliated with
Mashhad University of Medical Science in 2018, which may limit
the ability to generalize the results to the other medical centers in
the country.
Conclusion
The economic impact of stroke is considerable. The premature
deaths and disabilities resulting from strokes accounted for the
main productivity losses and all societal costs of stroke. Healthcare
providers and decision makers are recommended to expand
healthy lifestyle choices in society to control hypertension and
decrease the burden of stroke, especially in elderly age groups.
Nevertheless, it seems necessary to design a registration system at
the national level for stroke patients.Article and Author Information
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